Business Context and Reporting Period
Sunshine Biopharma Inc., an emerging growth company incorporated in Colorado, filed this Form 8-K on June 22, 2017. The report addresses the completion of an independent valuation of the company's issued and outstanding shares, a requirement stemming from prior Subscription Agreements.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The primary financial data point disclosed is the estimated Fair Market Value of the company's equity.
- Valuation Date: March 31, 2017
- Valuation Firm: MNP LLP
- Estimated En Bloc Fair Market Value: $977.0 million to $1,133.0 million
Material Changes
The filing reports the issuance of the valuation report by MNP LLP. The company explicitly states that it is not anticipated that the results of this valuation will have any impact on its financial statements. No material changes to financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, outlook, or discussion of risks and contingencies beyond the context of the valuation. The company confirms that MNP LLP is independent, has no ownership interest in Sunshine Biopharma, and that their fees were not contingent on the valuation conclusions.
Investor Verification Checklist
- Verify the full text of the Press Release attached as Exhibit 99.6 for additional context on the valuation methodology.
- Review the Subscription Agreements referenced to understand the specific terms requiring this valuation.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Note that the filing text does not provide current revenue, cash flow, or debt figures; refer to the most recent Form 10-K or 10-Q for operational data.